Trial Profile
A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin
- Indications Orofacial cancer; Oropharyngeal cancer
- Focus Adverse reactions; Biomarker
- 08 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 15 Aug 2011 Planned end date 1 May 2011 added as reported by ClinicalTrials.gov.
- 15 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.